New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
10:00 EDTALB, WPX, TSN, SBH, PFS, PCYC, MSTR, MTDR, MWE, LSTR, ONE, FGP, FDO, DCO, COST, COLM, BOH, AGNC, ZIONOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Albemarle (ALB) upgraded to Buy from Hold at Topeka... American Capital Agency (AGNC) upgraded to Buy from Hold at Wunderlich... Bank of Hawaii (BOH) upgraded to Buy from Neutral at DA Davidson... Columbia Sportswear (COLM) upgraded to Hold from Sell at McAdams Wright... Costco (COST) upgraded to Conviction Buy from Neutral at Goldman... Ducommun (DCO) upgraded to Buy from Neutral at DA Davidson... Family Dollar (FDO) upgraded to Neutral from Underweight at Piper Jaffray... Ferrellgas Partners LP (FGP) upgraded to Neutral from Sell at Citigroup... Higher One (ONE) upgraded to Overweight from Underweight at Piper Jaffray... Landstar System (LSTR) upgraded to Buy from Hold at BB&T... MarkWest Energy (MWE) upgraded to Buy from Hold at Wunderlich... Matador (MTDR) upgraded to Outperform from Market Perform at BMO Capital... MicroStrategy (MSTR) upgraded at JMP Securities... Pharmacyclics (PCYC) upgraded to Outperform from Market Perform at Leerink... Provident Financial (PFS) upgraded at Sterne Agee... Sally Beauty (SBH) upgraded to Buy from Neutral at Citigroup... Tyson Foods (TSN) upgraded to Buy from Hold at Miller Tabak... WPX Energy (WPX) upgraded to Accumulate from Hold at Tudor Pickering... Zions Bancorp (ZION) upgraded at Bernstein.
News For ALB;AGNC;BOH;COLM;COST;DCO;FDO;FGP;ONE;LSTR;MWE;MTDR;MSTR;PCYC;PFS;SBH;TSN;WPX;ZION From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 17, 2014
17:36 EDTFDOFamily Dollar says will review Elliot notice on directors in due course
Subscribe for More Information
17:11 EDTWPXIntegrated Core Strategies reports 4.6% passive stake in WPX Energy
Subscribe for More Information
16:09 EDTFDOElliott Advisors expresses concerns over Family Dollar merger, nominates slate
Subscribe for More Information
09:07 EDTTSNProtein stock pullback on Sanderson comments overdone, says BMO Capital
BMO Capital views yesterday's decline in Sanderson Farms (SAFM), Pilgrim's Pride (PPC) and Tyson Foods (TSN) as an overreaction to Sanderson's comments regarding breast prices falling to year-ago levels for the next four months. BMO notes that breast prices always dip in the fall. Following Sanderson's investor day, BMO said it sees a greater probability of chicken margins remaining at near-record levels in 2015. It keeps an Outperform rating on the stock.
08:57 EDTPCYCPharmacyclics price target raised to $188 from $185 at Roth Capital
Subscribe for More Information
08:51 EDTPCYCPharmacyclics announces European approval for Imbruvica
Subscribe for More Information
08:34 EDTPCYCPharmacyclics management to meet with JPMorgan
Subscribe for More Information
07:39 EDTTSNChicken stock sell-off yesterday overdone, says JPMorgan
Subscribe for More Information
October 16, 2014
15:35 EDTTSNSanderson Farms falls following investor day meeting
Subscribe for More Information
14:47 EDTPCYCRoche in pact with Pharmacyclics to evaluate Imbruvica, Gazyva combo
Subscribe for More Information
October 15, 2014
11:27 EDTFDOOptions with decreasing implied volatility
Options with decreasing implied volatility: EXAS INO ATLS LOCO OPK INFY EUO FDO
06:16 EDTPCYCPharmacyclics initiated with a Buy at Citigroup
Subscribe for More Information
October 14, 2014
16:44 EDTMTDRMatador reaffirms remaining FY14 guidance, still sees FY15 BOE production up 50%
Subscribe for More Information
16:37 EDTMTDRMatador increases FY14 oil production guidance range to 3.2M-3.3M barrels
Subscribe for More Information
16:35 EDTMTDRMatador reports Q3 production up 19% to 1.5 MBOE
Matador Resources provided the following update of its ongoing operations. Matador is pleased to announce its quarterly production results for the three months ended September 30, which were the best quarterly oil equivalent production and quarterly oil production results in the company’s history. Oil equivalent production increased 19% year over year from approximately 1.24 MBOE or an average of about 13,500 BOE per day in 3Q13 to approximately 1.5 MBOE or an average of about 16,100 BOE per day in Q3. Oil equivalent production increased approximately 6% sequentially quarter over quarter from approximately 1.4 MBOE or an average of about 15,400 BOE per day in the second quarter of 2014 and increased 38% from approximately 1.1 MBOE or an average of about 11,900 BOE per day in Q1.
08:43 EDTMTDRMatador upgraded to Accumulate from Hold at KLR Group
Subscribe for More Information
05:58 EDTCOSTCostco debuts in China through Alibaba Tmall platform
Subscribe for More Information
October 13, 2014
12:01 EDTFDOOptions with decreasing implied volatility
Options with decreasing implied volatility: EXAS INFY YUM FDO HSY
08:05 EDTPCYCBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
07:09 EDTLSTRLandstar System removed from short-term buy list at Deutsche Bank
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use